We are live on
!
Find out more
EAM
Eventide Asset Management Portfolio holdings
AUM
$6.05B
1-Year Est. Return
76.64%
This Fund
S&P 500
This Quarter
Est. Return
+23.31%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$916M
AUM Growth
+$200M
(+28%)
Cap. Flow
+$82.6M
Cap. Flow
% of AUM
9.02%
Top 10 Holdings %
Top 10 Hldgs %
26.61%
Holding
112
New
9
Increased
29
Reduced
6
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MNDT
Mandiant, Inc. Common Stock
MNDT
|
+$17.7M |
| 2 |
Trinity Industries
TRN
|
+$17.1M |
| 3 |
SPLK
Splunk Inc
SPLK
|
+$9.6M |
| 4 |
NRG Energy
NRG
|
+$6.27M |
| 5 |
XPO
XPO
|
+$6.11M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agios Pharmaceuticals
AGIO
|
+$15.5M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$6.68M |
| 3 |
Akebia Therapeutics
AKBA
|
+$3.68M |
| 4 |
CBST
CUBIST PHARMACEUTICALS INC
CBST
|
+$1.92M |
| 5 |
Arrowhead Research
ARWR
|
+$1.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.22% |
| 2 | Technology | 16.49% |
| 3 | Consumer Discretionary | 14.21% |
| 4 | Industrials | 9.04% |
| 5 | Energy | 4.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Teleflex
TFX
$5.86B
| $666K | 0.07% |
5,800
| – | – |
|
|
XOMA
102
DELISTED
Xoma
XOMA
| $636K | 0.07% |
8,860
| – | – |
|
|
RPTP
103
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
| $316K | 0.03% |
30,000
-10,400
| -26% | -$102K |
|
104
Verastem
VSTM
$536M
| $191K | 0.02% |
1,742
| – | – |
|
|
LITS
105
Lite Strategy Inc
LITS
$33.6M
| $109K | 0.01% |
1,279
-8,801
| -87% | -$1.16M |
|
106
Larimar Therapeutics
LRMR
$398M
| $19K | ﹤0.01% |
+50
| New | +$12.9K |
|
|
107
Akebia Therapeutics
AKBA
$362M
| – | – |
-166,200
| Closed | -$3.68M |
|
|
108
Arrowhead Research
ARWR
$12.3B
| – | – |
-114,700
| Closed | -$1.69M |
|
|
VIRX
109
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-437
| Closed | -$655K |
|
|
AEGR
110
DELISTED
Aegerion Pharmaceuticals
AEGR
| – | – |
-20,000
| Closed | -$668K |
|
|
SZYM
111
DELISTED
SOLAZYME INC COM STK (DE)
SZYM
| – | – |
-190,000
| Closed | -$1.42M |
|
|
CBST
112
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| – | – |
-29,000
| Closed | -$1.92M |
|
Similar funds
HPG
EMPI
RCG
JWBC
AAM
AA
CM
CIS
Eventide Asset Management's Q4 2014 Portfolio in Review
As of Q4 2014, Eventide Asset Management held 112 positions worth $916M, up 28% from $716M the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Eventide Asset Management deployed $82.6M of net new capital in Q4 2014, opening 9 new positions and adding to 29 existing holdings. Its largest new stake was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 29% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $15.5M trimmed.
- Eventide Asset Management's largest Q4 2014 buy was Mandiant, Inc. Common Stock: 575,600 shares worth $18.2M.
- Eventide Asset Management added most to NRG Energy in Q4 2014, an estimated $6.27M increase.
- Eventide Asset Management's biggest Q4 2014 reduction was Agios Pharmaceuticals, cutting an estimated $15.5M.
- Eventide Asset Management fully exited Akebia Therapeutics in Q4 2014, selling an estimated $3.68M.
- Eventide Asset Management's ten largest holdings make up 27% of its $916M portfolio in Q4 2014.
- Eventide Asset Management opened 9 new positions and closed 6 in Q4 2014.
- Eventide Asset Management's portfolio value rose 28% quarter-over-quarter to $916M.
Based on Eventide Asset Management's 13F filing for Q4 2014, filed 12 Feb 2015.